| DELCATH SYS NEW DL-,01 |
| USA |
| Gesundheit |
| US24661P8077 / A2PT5P |
| DV3R (Frankfurt) / DCTH (NASDAQ) |
| FRA:DV3R, ETR:DV3R, DV3R:GR, NASDAQ:DCTH |
| - |
| http://delcath.com/ |
|
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liv..
>Volltext.. |
| 461.6 Mio. EUR |
| 379.15 Mio. EUR |
| 85.65 Mio. EUR |
| -1.19 Mio. EUR |
| 0.48 Mio. EUR |
| 0.01 EUR |
| 2.21 Mio. EUR |
| 42.66 Mio. EUR |
| 17.58 Mio. EUR |
| 7.22 |
| 40.12% |
| -75.42% |
| - |
| - |
| - |
| - |
| DELCATH |
| 09.11.26 |
|
||||
|
||||
|
||||
|
||||
|